Gemcitabine is a nucleoside analog that is currently the best available single-agent chemotherapeutic drug for pancreatic cancer. However, efficacy is limited by our inability to deliver sufficient active metabolite into cancer cells without toxic effects on normal tissues. Targeted delivery of gemcitabine into cancer cells could maximize effectiveness and concurrently minimize toxic side effects by reducing uptake into normal cells. Most pancreatic cancers overexpress epidermal growth factor receptor (EGFR), a trans-membrane receptor tyrosine kinase. We utilized a nuclease resistant RNA aptamer that binds and is internalized by EGFR on pancreatic cancer cells to deliver gemcitabine-containing polymers into EGFR-expressing cells and inhibit cell proliferation in vitro. This approach to cell type–specific therapy can be adapted to other targets and to other types of therapeutic cargo.
Get full access to this article
View all access options for this article.
References
1.
ACHIWAH., OGURIT., SATOS., MAEDAH., NIIMIT., UEDAR.2004. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci., 95:753–757.
2.
BAGALKOTV., FAROKHZADO.C., LANGERR., JONS.2006. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem. Int. Ed. Engl., 45:8149–8152.
3.
BATESP.J., LABERD.A., MILLERD.M., THOMASS.D., TRENTJ.O.2009. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol., 86:151–164.
4.
BUNKAD.H., PLATONOVAO., STOCKLEYP.G.2010. Development of aptamer therapeutics. Curr. Opin. Pharmacol., 10:557–562.
5.
BURRISH.A.3rd, MOOREM.J., ANDERSENJ., GREENM.R., ROTHENBERGM.L., MODIANOM.R., CRIPPSM.C., PORTENOYR.K., STORNIOLOA.M., TARASSOFFP.et al.1997. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15:2403–2413.
6.
CERCHIAL., GIANGRANDEP.H., MCNAMARAJ.O., DE FRANCISCISV.2009. Cell-specific aptamers for targeted therapies. Methods Mol. Biol., 535:59–78.
7.
CHUT.C., MARKSJ.W.3RD, LAVERYL.A., FAULKNERS., ROSENBLUMM.G., ELLINGTONA.D., LEVYM.2006. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res., 66:5989–5992.
8.
CONRADF., HANNEA., GAURR.K., KRUPPG.1995. Enzymatic synthesis of 2′-modified nucleic acids: identification of important phosphate and ribose moieties in RNase P substrates. Nucleic Acids Res., 23:1845–1853.
9.
CONROYT., DESSEIGNEF., YCHOUM., BOUCHEO., GUIMBAUDR., BECOUARNY., ADENISA., RAOULJ.L., GOURGOU-BOURGADES., DE LA FOUCHARDIEREC.et al.2011. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med., 364:1817–1825.
ELLINGTONA.D., SZOSTAKJ.W.1990. In vitro selection of RNA molecules that bind specific ligands. Nature, 346:818–822.
12.
FAROKHZADO.C., CHENGJ., TEPLYB.A., SHERIFII., JONS., KANTOFFP.W., RICHIEJ.P., LANGERR.2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A., 103:6315–6320.
13.
FOWLERJ.D., BROWNJ.A., JOHNSONK.A., SUOZ.2008. Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase. J. Biol. Chem., 283:15339–15348.
14.
GANH.K., WALKERF., BURGESSA.W., RIGOPOULOSA., SCOTTA.M., JOHNST.G.2007. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers. Implications for combination therapy with monoclonal antibody 806. J. Biol. Chem., 282:2840–2850.
15.
GAURR.K., KRUPPG.1993. Modification interference approach to detect ribose moieties important for the optimal activity of a ribozyme. Nucleic Acids Res., 21:21–26.
16.
GIOVANNETTIE., DEL TACCAM., MEYV., FUNELN., NANNIZZIS., RICCIS., ORLANDINIC., BOGGIU., CAMPANID., DEL CHIAROM.et al.2006. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res., 66:3928–3935.
17.
HANSELT.T., KROPSHOFERH., SINGERT., MITCHELLJ.A., GEORGEA.J.2010. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Disc., 9:325–338.
18.
HEK., HASANA., KRZYZANOWSKAB., SHAWB.R.1998. Synthesis and separation of diastereomers of ribonucleoside 5′-(alpha-P-borano) triphosphates. J. Org. Chem., 63:5769–5773.
19.
HUANGP., CHUBBS., HERTELL.W., GRINDEYG.B., PLUNKETTW.1991. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51:6110–6117.
20.
KINDLERH.L., FRIBERGG., SINGHD.A., LOCKERG., NATTAMS., KOZLOFFM., TABERD.A., KARRISONT., DACHMANA., STADLERW.M.et al.2005. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 23:8033–8040.
21.
KNUDSENS.M., ROBERTSONM.P., ELLINGTONA.D.2002. In vitro selection using modified or unnatural nucleotides. Curr. Protoc. Nucleic Acid Chem.Chapter9Unit 9.6.
22.
KROEPJ.R., LOVESW.J., VAN DER WILTC.L., ALVAREZE., TALIANIDISI., BOVENE., BRAAKHUISB.J., VAN GROENINGENC.J., PINEDOH.M., PETERSG.J.2002. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther., 1:371–376.
23.
LEVY-NISSENBAUME., RADOVIC-MORENOA.F., WANGA.Z., LANGERR., FAROKHZADO.C.2008. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol., 26:442–449.
24.
LIN., LARSONT., NGUYENH.H., SOKOLOVK.V., ELLINGTONA.D.2010. Directed evolution of gold nanoparticle delivery to cells. Chemical communications, 46:392–394.
25.
LIN., NGUYENH.H., BYROMM., ELLINGTONA.D.2011. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS One, 6:e20299.
26.
LUDWIGJ., ECKSTEINF.1989. Rapid and efficient synthesis of nucleoside 5′-O-(1-thiotriphosphate)s, 5′-triphosphates and 2′,3′-cyclophosphorothioates using 2-chloro-4H-1,3,2-benzodioxaphosphorin-4-one. J. Org. Chem., 54:631–635.
27.
MACKEYJ.R., MANIR.S., SELNERM., MOWLESD., YOUNGJ.D., BELTJ.A., CRAWFORDC.R., CASSC.E.1998. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res., 58:4349–4357.
28.
MCNAMARAJ.O.2ND, ANDRECHEKE.R., WANGY., VILESK.D., REMPELR.E., GILBOAE., SULLENGERB.A., GIANGRANDEP.H.2006. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol., 24:1005–1015.
29.
MILLIGANJ.F., GROEBED.R., WITHERELLG.W., UHLENBECKO.C.1987. Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res., 15:8783–8798.
30.
MOOREM.J., GOLDSTEIND., HAMMJ., FIGERA., HECHTJ.R., GALLINGERS., AUH.J., MURAWAP., WALDED., WOLFFR.A.et al.2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 25:1960–1966.
31.
NAKANOY., TANNOS., KOIZUMIK., NISHIKAWAT., NAKAMURAK., MINOGUCHIM., IZAWAT., MIZUKAMIY., OKUMURAT., KOHGOY.2007. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br. J. Cancer, 96:457–463.
32.
OETTLEH., POSTS., NEUHAUSP., GELLERTK., LANGREHRJ., RIDWELSKIK., SCHRAMMH., FAHLKEJ., ZUELKEC., BURKARTC.et al.2007. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. Jama, 297:267–277.
33.
OLIVEK.P., JACOBETZM.A., DAVIDSONC.J., GOPINATHANA., MCINTYRED., HONESSD., MADHUB., GOLDGRABENM.A., CALDWELLM.E., ALLARDD.et al.2009. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science, 324:1457–1461.
34.
PADILLAR., SOUSAR.1999. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP)Nucleic Acids Res., 27:1561–1563.
35.
PATRAC.R., BHATTACHARYAR., WANGE., KATARYAA., LAUJ.S., DUTTAS., MUDERSM., WANGS., BUHROWS.A., SAFGRENS.L.et al.2008. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res., 68:1970–1978.
36.
PHILIPP., BENEDETTIJ., FENOGIO-PREISERC., ZALUPSKIM., LENZH., O'REILLYE., WONGR., ATKINSJ., ABBRUZZESEJ., BLANKEC.2007. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. J. Clin. Oncol., 25:LBA4509.
37.
ROCHA-LIMAC.M., SOARESH.P., RAEZL.E., SINGALR.2007. EGFR targeting of solid tumors. Cancer Control, 14:295–304.
38.
RUIZ VAN HAPERENV.W., VEERMANG., VERMORKENJ.B., PETERSG.J.1993. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol., 46:762–766.
39.
SIEGELR., WARDE., BRAWLEYO., JEMALA.2011. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 61:212–236.
40.
SOUNDARARAJANS., WANGL., SRIDHARANV., CHENW., COURTENAY-LUCKN., JONESD., SPICERE.K., FERNANDESD.J.2009. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells. Mol. Pharmacol., 76:984–991.
41.
SOUSAR., PADILLAR.1995. A mutant T7 RNA polymerase as a DNA polymerase. EMBO, 14:4609–4621.
42.
TUERKC., GOLDL.1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science, 249:505–510.
43.
ULLRICHA., SCHLESSINGERJ.1990. Signal transduction by receptors with tyrosine kinase activity. Cell, 61:203–212.
44.
VIEIRAA.V., LAMAZEC., SCHMIDS.L.1996. Control of EGF receptor signaling by clathrin-mediated endocytosis. Science, 274:2086–2089.
45.
WICKSTROME.1986. Oligodeoxynucleotide stability in subcellular extracts and culture media. J. Biochem. Biophys. Methods, 13:97–102.
46.
XIONGH.Q., ROSENBERGA., LOBUGLIOA., SCHMIDTW., WOLFFR.A., DEUTSCHJ., NEEDLEM., ABBRUZZESEJ.L.2004. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J. Clin. Oncol., 22:2610–2616.
47.
ZHANGY., CHENY., HAND., OCSOYI., TANW.2010. Aptamers selected by cell-SELEX for application in cancer studies. Bioanalysis, 2:907–918.
48.
ZHOUJ., ROSSIJ.J.2011. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides, 21:1–10.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
